BSPM - Biostar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.14
+0.10 (+4.90%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.04
Open2.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.02 - 2.21
52 Week Range1.18 - 3.09
Volume37,825
Avg. Volume107,706
Market Cap5.644M
Beta0.54
PE Ratio (TTM)6.29
EPS (TTM)0.34
Earnings DateApr 11, 2018 - Apr 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • December Undervalued Opportunities – Biostar Pharmaceuticals And More
    Simply Wall St.25 days ago

    December Undervalued Opportunities – Biostar Pharmaceuticals And More

    Biostar Pharmaceuticals and Goodrich Petroleum are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...

  • PR Newswire2 months ago

    Biostar Regains Compliance with NASDAQ Continued Listing Requirement

    XIANYANG, China, Dec. 4, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced that on November 30, 2017, it received a letter from the NASDAQ Listing Qualifications Staff ("Staff") notifying the Company that it regained compliance with NASDAQ's Listing Rule 5250(c)(1) for continued listing on NASDAQ Capital Market and the Staff considers the matter closed. On August 22, 2017, the Company received a Staff notification letter advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal year ended June 30, 2017, the Company was not in compliance with NASDAQ Listing Rule 5250(c)(1).

  • Network-1 Technologies And Other Top Undervalued Stocks
    Simply Wall St.2 months ago

    Network-1 Technologies And Other Top Undervalued Stocks

    Network-1 Technologies and Goodrich Petroleum are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...

  • PR Newswire2 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Nine Months Ended September 30, 2017

    XIANYANG, China , Nov. 20, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and ...

  • PR Newswire2 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2017

    XIANYANG, China , Nov. 15, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and ...

  • Is Biostar Pharmaceuticals Inc’s (BSPM) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.3 months ago

    Is Biostar Pharmaceuticals Inc’s (BSPM) Balance Sheet Strong Enough To Weather A Storm?

    Investors are always looking for growth in small-cap stocks like Biostar Pharmaceuticals Inc (NASDAQ:BSPM), with a market cap of USD $4.37M. However, an important fact which most ignore is: howRead More...

  • ACCESSWIRE3 months ago

    3 Trending Biotech Stocks To Watch On Monday

    CORAL GABLES, FL / ACCESSWIRE / October 9, 2017 / Here are three trending biotech stocks to watch during Monday's trading session: GT Biopharma Inc. (GTBP) , a targeted immunotherapies company with near ...

  • PR Newswire5 months ago

    Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

    XIANYANG, China, Aug. 28, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 22, 2017 it received a notification letter from Nasdaq Listing Qualifications ("Nasdaq") advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal year ended June 30, 2017, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. The Company is required within 60 calendar days of the Nasdaq notification to submit a plan of compliance with the foregoing continued listing deficiency. If the Company's plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days (or until February 12, 2018) to regain compliance.

  • PR Newswire8 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2017

    XIANYANG, China, May 19, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health ...

  • PR Newswire9 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2016

    XIANYANG, China, April 13, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and ...